Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Amphivena Therapeutics logo — Empowering Cancer Patients with Dual-Action Immuno-Oncology...

Amphivena Therapeutics

Empowering Cancer Patients with Dual-Action Immuno-Oncology Biologics

Founded 2012 Series C Total: $135.69M Biotechnology, Health Care +1

General Information

Company Name Amphivena Therapeutics
Founded Year 2012
Founders / Decision Makers
Team member Team member Team member
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Amphivena Therapeutics. To contact Amphivena Therapeutics, visit amphivena.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Amphivena Therapeutics compare?

A PDF of Amphivena Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Amphivena Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Amphivena Therapeutics

Amphivena Therapeutics is a biotechnology startup established in 2012 and headquartered in South San Francisco, California. The company's focus is on immuno-oncology, aiming to empower cancer patients with dual-action biologics through its ReSTORE platform. This platform is designed to combat immune suppression and stimulate T cell effector function in cancer patients. By incorporating elements of avidity, target selectivity, and enhanced safety within a single molecule, Amphivena Therapeutics can engineer the biologics to include additional features for solid tumor targeting and direct tumor cell elimination. In September 2019, Amphivena Therapeutics secured a significant $62.00M Series C investment. The funding was provided by a group of prominent investors including MPM Capital, Qiming Venture Partners, Aju IB Investment, Clough Capital, Franklin Berger, Mérieux Equity Partners, ND Capital, Solasta Ventures, Industrial Investors Group, and Newton Investment Management. This investment signifies confidence in the potential of Amphivena Therapeutics and its innovative approach to immuno-oncology, positioning the startup for continued growth and impact in the healthcare and biotechnology industries.

Business keywords: Amphivena Therapeutics, Cancer Treatment, Immuno-Oncology, Biologics, Clinical-stage, ReSTORE Platform, Dual-Action Biologics, Tumor Targeting, Avidity, T Cell Activation, Immune Suppression, Solid Tumor Therapy, South San Francisco, California, Healthcare Innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $62.00M 10
MPM Capital Qiming Venture Partners Aju IB Investment
MPM Capital, Qiming Venture Partners +8
24 Sep 2019
Venture Round $38.69M -
10 Dec 2018
Series B $7.00M -
26 Jul 2017
Venture Round $14.00M -
04 May 2015
Series A $14.00M -
15 Jul 2013

Amphivena Therapeutics Alternatives & Competitors

View All Alternatives
Amphivena Therapeutics vs
Oxford BioTherapeutics
Oxford BioTherapeutics United Kingdom

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

66 employees
Biotechnology, Health Care
Amphivena Therapeutics vs
ONK Therapeutics
ONK Therapeutics Ireland

Pioneering optimally engineered NK cell therapies to cure patients with cancer.

Series A
20 employees
Biotechnology, Health Care
Amphivena Therapeutics vs
Harpoon Therapeutics
Harpoon Therapeutics United States

SPEARHEADING IMMUNOTHERAPIES

Post-IPO Equity
33 employees
Biotechnology, Health Care
View all alternatives

FAQ About Amphivena Therapeutics

Empowering Cancer Patients with Dual-Action Immuno-Oncology Biologics
Amphivena Therapeutics was founded in 2012.
Amphivena Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Amphivena Therapeutics, Cancer Treatment, Immuno-Oncology and Biologics.
Amphivena Therapeutics has completed 5 funding rounds, raising a total of $135.69M. The latest funding stage is Series C.
Top alternatives and competitors to Amphivena Therapeutics include Oxford BioTherapeutics, ONK Therapeutics, Harpoon Therapeutics, OncXerna Therapeutics , TransCode Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amphivena Therapeutics and Oxford BioTherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Amphivena Therapeutics, https://bouncewatch.com/company/amphivena-therapeutics, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout